Argenx Se Adr

argenx SE, a commercial‑stage biopharma headquartered in the Netherlands, markets VYGART for myasthenia gravis and develops the lead antibody efgartigimod for multiple autoimmune indications, backed by strategic partnerships with AbbVie, LEO Pharma and others.

Headquarters: Belgium (BEL)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical Practices

Employees: 1,599
HQ: Amsterdam

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
ARGX	Argenx Se Adr Cap: 48.8B \| P/E: 33.7	EQUITY	NMS	USD	US04016X1019	Active	📈